Syros Net Debt To E B I T D A from 2010 to 2024
| SYRS Stock | USD 0.27 0.02 8.00% |
Net Debt To EBITDA | First Reported 2010-12-31 | Previous Quarter 0.49270651 | Current Value 0.47 | Quarterly Volatility 1.07166298 |
Check Syros Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Syros Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.1 M, Interest Expense of 5.4 M or Selling General Administrative of 18.9 M, as well as many indicators such as Price To Sales Ratio of 21.1, Dividend Yield of 0.0 or PTB Ratio of 13.91. Syros financial statements analysis is a perfect complement when working with Syros Pharmaceuticals Valuation or Volatility modules.
Syros | Net Debt To E B I T D A |
Latest Syros Pharmaceuticals' Net Debt To E B I T D A Growth Pattern
Below is the plot of the Net Debt To E B I T D A of Syros Pharmaceuticals over the last few years. It is a leverage ratio that indicates a company's ability to pay off its incurred debt. It compares a company's net debt (total debt minus cash) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). Syros Pharmaceuticals' Net Debt To EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Syros Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Net Debt To E B I T D A | 10 Years Trend |
|
Net Debt To E B I T D A |
| Timeline |
Syros Net Debt To E B I T D A Regression Statistics
| Arithmetic Mean | 0.96 | |
| Geometric Mean | 0.69 | |
| Coefficient Of Variation | 112.12 | |
| Mean Deviation | 0.64 | |
| Median | 0.49 | |
| Standard Deviation | 1.07 | |
| Sample Variance | 1.15 | |
| Range | 4.3697 | |
| R-Value | (0.13) | |
| Mean Square Error | 1.22 | |
| R-Squared | 0.02 | |
| Significance | 0.65 | |
| Slope | (0.03) | |
| Total Sum of Squares | 16.08 |
Syros Net Debt To E B I T D A History
About Syros Pharmaceuticals Financial Statements
Syros Pharmaceuticals shareholders use historical fundamental indicators, such as Net Debt To E B I T D A, to determine how well the company is positioned to perform in the future. Although Syros Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Syros Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Syros Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Debt To EBITDA | 0.49 | 0.47 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Syros Stock Analysis
When running Syros Pharmaceuticals' price analysis, check to measure Syros Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syros Pharmaceuticals is operating at the current time. Most of Syros Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syros Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syros Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syros Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.